Teva's migraine drug clears another hurdle, aims for launch in 2018

JERUSALEM (Reuters) - Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraines cleared another late-stage study, setting it on course for U.S regulatory approval and launch in the second half of 2018.